Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC-Reference-Cited by-同舟云学术

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

Published:2019-01-28 Issue:3 Volume:36 Page:670-683
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Hebart Holger^ORCID,Kiehl Michael^ORCID,Tomasek Jiri^ORCID,Csoszi Tibor^ORCID,Koukakis Reija,Kafatos George,Kuhn Anja,Bjorklof Katja,Demonty Gaston,Buchler Tomas

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-019-0874-6.pdf

Reference27 articles.

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. http://globocan.iarc.fr . Accessed 15 Jan 2018.

2. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2(6):459–71.

3. Pazdur R, Coia L, Wagman LD, Ayoub JP. Colorectal and anal cancers. Cancer management: a multidisciplinary approach. Melville: PRR; 1999. p. 149–75.

4. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.

5. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18(1):7–15.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?;Drugs & Therapy Perspectives;2022-05

2. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center;The Oncologist;2021-10-01

3. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers;Clinical Colorectal Cancer;2020-06